Overview

Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer

Status:
Active, not recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This is an exploratory interventional study that initiates standard-of-care anti-estrogen treatment preoperatively for four weeks.
Phase:
Phase 2
Details
Lead Sponsor:
Medical College of Wisconsin
Treatments:
Anastrozole
Aromatase Inhibitors
Estrogens
Exemestane
Hormones
Letrozole
Tamoxifen